Payment overview · 2025
General Payments
$176.42
8 reported records · 6 companies
Healthcare provider profile · identity verified
Mary Lou Freitag
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MYRTLE POINT, OR · NPI 1962090621
Verified facts
What the public records show
CMS Open Payments records show Mary Lou Freitag received $176.42 in general payments during 2025 across 8 reported records.
Novartis Pharmaceuticals Corporation accounted for 25.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.62 | 25.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.86 | 19.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.56 | 15.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.64 | 15.1% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $24.60 | 13.9% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $19.14 | 10.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $160.43 | 7 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.62 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $26.64 | 1 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 298 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 296 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 272 | 41 |
| Lisinopril | Lisinopril | 254 | 77 |
| Furosemide | Furosemide | 244 | 68 |
| Losartan Potassium | Losartan Potassium | 167 | 51 |
| Omeprazole | Omeprazole | 140 | 45 |
| Potassium Chloride | Potassium Chloride | 135 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 37 |
| Tramadol Hcl | Tramadol Hcl | 123 | 25 |
| Gabapentin | Gabapentin | 116 | 37 |
| Metformin Hcl | Metformin Hcl | 113 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 32 |
| Trazodone Hcl | Trazodone Hcl | 100 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 39 |
| Carvedilol | Carvedilol | 88 | 28 |
| Celecoxib | Celecoxib | 77 | 29 |
| Pregabalin | Pregabalin | 75 | 15 |
| Spironolactone | Spironolactone | 75 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 70 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 69 | 22 |
| Lorazepam | Lorazepam | 68 | 27 |
| Prednisone | Prednisone | 67 | 30 |
| Glipizide | Glipizide | 64 | 20 |
| Metformin Hcl Er | Metformin Hcl | 63 | 21 |
| Eliquis | Apixaban | 59 | 15 |
| Clonidine Hcl | Clonidine Hcl | 56 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 18 |
| Simvastatin | Simvastatin | 48 | 15 |
| Warfarin Sodium | Warfarin Sodium | 48 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 36 |
| Meloxicam | Meloxicam | 45 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 12 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 12 |
| Ondansetron Odt | Ondansetron | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 14 |
| Finasteride | Finasteride | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 18 |
| Estradiol | Estradiol | 34 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 12 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 12 |
| Nystatin | Nystatin | 28 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Allopurinol | Allopurinol | 26 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Famotidine | Famotidine | 26 | 11 |
| Atenolol | Atenolol | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 18 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $176.42 · 8 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, BREZTRI, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, LEQVIO, MAVYRET, REZDIFFRA, The Cologuard Plus Collection Kit | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error